|
Sep 24
|
Sector Update: Health Care Stocks Mixed Late Afternoon
|
|
Sep 24
|
Market Chatter: Sanofi Consumer Health Division Attracts Bids From 2 Private Equity Firms
|
|
Sep 6
|
Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
|
|
Sep 6
|
Men taking valproate and their partners warned to use contraception by MHRA
|
|
Sep 6
|
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
|
|
Sep 5
|
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
|
|
Sep 3
|
Why Sanofi Stock Was Robustly Healthy Today
|
|
Sep 3
|
Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials
|
|
Sep 3
|
Sanofi finds a silver lining in mixed MS drug results
|
|
Sep 2
|
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
|
|
Sep 2
|
Sanofi reports data from Phase III multiple sclerosis trials of tolebrutinib
|
|
Sep 2
|
Sanofi Multiple Sclerosis Drug Delays Disability Progression in Trial
|
|
Sep 2
|
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
|
|
Aug 28
|
Sanofi (SNY): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
|
Aug 28
|
Five alternatives to Mag 7 stocks if you missed out on Nvidia
|
|
Aug 9
|
Sanofi: Information concerning the total number of voting rights and shares - July 2024
|
|
Aug 9
|
Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
|
|
Aug 8
|
Sanofi's Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant
|
|
Aug 8
|
Sanofi’s Sarclisa wins in transplant-eligible multiple myeloma trial
|
|
Aug 8
|
Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus
|